BACKGROUND: To identify the potential prognostic role of the neutrophil/lymphocyte (N/L) ratio in larynx carcinoma. MATERIALS AND METHODS: Oncologic archive charts of patients with a larynx carcinoma diagnosis between the years 2010 and 2013 were retrospectively reviewed. The inclusion criterion was to be available with hemogram test prior to diagnostic procedure. Patients undergoing septorinoplasty comprised the control group. RESULTS: There were 65 cases in the study and 42 cases in control group meeting inclusion criteria. In general a non-significant increase in N/L ratio was observed with increasing tumor size and stage (p>0.05) in larynx carcinoma. The N/L ratio was found to be significantly higher in larynx carcinoma compared to control group (p=0.004). CONCLUSIONS: In conclusion, the N/L ratio was shown to be significantly increased in larynx carcinomas compared to control group. Further studies are needed to assess any prognostic role.
BACKGROUND: To identify the potential prognostic role of the neutrophil/lymphocyte (N/L) ratio in larynx carcinoma. MATERIALS AND METHODS: Oncologic archive charts of patients with a larynx carcinoma diagnosis between the years 2010 and 2013 were retrospectively reviewed. The inclusion criterion was to be available with hemogram test prior to diagnostic procedure. Patients undergoing septorinoplasty comprised the control group. RESULTS: There were 65 cases in the study and 42 cases in control group meeting inclusion criteria. In general a non-significant increase in N/L ratio was observed with increasing tumor size and stage (p>0.05) in larynx carcinoma. The N/L ratio was found to be significantly higher in larynx carcinoma compared to control group (p=0.004). CONCLUSIONS: In conclusion, the N/L ratio was shown to be significantly increased in larynx carcinomas compared to control group. Further studies are needed to assess any prognostic role.
Authors: Nikhil V Kotha; Rohith S Voora; Alex S Qian; Abhishek Kumar; Edmund M Qiao; Tyler F Stewart; Brent S Rose; Ryan K Orosco Journal: Biomark Insights Date: 2021-10-11